Befotertinib—a viable alternative in EGFR-mutant advanced NSCLC?

The treatment landscape of epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer (NSCLC) has evolved rapidly, and osimertinib, a third-generation EGFR tyrosine-kinase inhibitor (TKI), has become the standard preferred treatment option in first-line settings based on its prolonged progression-free survival and better intracranial activity compared with first-generation and second-generation EGFR TKIs.1–3 Since these initial results, several phase 3 trials have explored novel, selective oral third-generation EGFR TKIs (table 1).